CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 115 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $262,000 | +26100.0% | 77,403 | +184192.9% | 0.00% | – |
Q3 2021 | $1,000 | -50.0% | 42 | -92.0% | 0.00% | – |
Q2 2021 | $2,000 | -50.0% | 523 | -36.9% | 0.00% | – |
Q1 2021 | $4,000 | +100.0% | 829 | +155.1% | 0.00% | – |
Q4 2020 | $2,000 | -33.3% | 325 | -6.9% | 0.00% | – |
Q3 2020 | $3,000 | +50.0% | 349 | -32.5% | 0.00% | – |
Q2 2020 | $2,000 | -98.9% | 517 | -99.6% | 0.00% | -100.0% |
Q1 2020 | $185,000 | -4.1% | 125,039 | +26.8% | 0.00% | – |
Q4 2019 | $193,000 | +3.8% | 98,588 | +170.8% | 0.00% | – |
Q3 2019 | $186,000 | +675.0% | 36,403 | +998.1% | 0.00% | – |
Q2 2019 | $24,000 | +300.0% | 3,315 | +667.4% | 0.00% | – |
Q1 2019 | $6,000 | +200.0% | 432 | +151.2% | 0.00% | – |
Q1 2018 | $2,000 | -85.7% | 172 | -92.8% | 0.00% | – |
Q2 2017 | $14,000 | +55.6% | 2,393 | +12.8% | 0.00% | – |
Q1 2017 | $9,000 | – | 2,121 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |